Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Vaxcyte Inc. announced the commencement of proposed offerings of common stock, pre-funded warrants, and convertible senior notes, aiming to raise funds for clinical development of its Vax-31 programs, manufacturing scale-up, and potential PCV program launches.
Vaxcyte has commenced underwritten offerings of $500 million in common stock and pre-funded warrants, and $500 million in convertible senior notes due 2032. Both offerings include 30-day over-allotment options.
Vaxcyte launched an underwritten public offering of USD 500 million of convertible senior notes due 2032. Notes are set to mature on Oct. 15, 2032, with the interest rate and initial conversion rate to be fixed at pricing. Underwriters have a 30-day option to buy up to an additional USD 75 million of notes to cover ove